Literature DB >> 11006009

Vigorous peripheral blood cytotoxic T cell response during the acute phase of hepatitis C virus infection.

M Cucchiarini1, A R Kammer, B Grabscheid, H M Diepolder, T J Gerlach, N Grüner, T Santantonio, J Reichen, G R Pape, A Cerny.   

Abstract

After infection by hepatitis C virus (HCV), a minority of patients develop acute symptomatic disease and some of them are able to clear the virus. In this study, we analyzed peripheral blood mononuclear cells from nine patients with acute symptomatic disease with respect to their cytotoxic T lymphocyte (CTL) response using a panel of HCV-derived peptides in a semiquantitative secondary in vitro culture system. We could detect early CTL responses in 67% of these patients. The CTL responses were directed against multiple viral epitopes, in particular within the structural (core 2-9, core 35-44, core 131-140, and core 178-187) and nonstructural regions of the virus (NS3 1073-1081, NS3 1406-1415, NS4 1807-1816, NS5 2252-2260, and NS5B 2794-2802). We compared the CTL responses displayed by recently and chronically infected HLA-A2-positive patients. Virus-specific CTLs were detectable in chronic carriers but the percentage of positive peptide-specific CTL responses was significantly higher in recently infected patients (P = 0.002). Follow-up of recently infected patients during subsequent disease development showed a significant decrease in the values and proportions of positive peptide-specific CTL responses (P = 0.002 and 0.013, respectively). Patients with limited viral replication exhibited significantly more vigorous early responses (P = 0.024). These data suggest a protective role for the early antiviral CTL response in HCV infection. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11006009     DOI: 10.1006/cimm.2000.1683

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  21 in total

Review 1.  Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis.

Authors:  Asmaa-Ibrahim Gomaa; Shahid-A Khan; Mireille-B Toledano; Imam Waked; Simon-D Taylor-Robinson
Journal:  World J Gastroenterol       Date:  2008-07-21       Impact factor: 5.742

2.  Identification and retrospective validation of T-cell epitopes in the hepatitis C virus genotype 4 proteome: an accelerated approach toward epitope-driven vaccine development.

Authors:  Karim M Abdel-Hady; Andres H Gutierrez; Frances Terry; Joe Desrosiers; Anne S De Groot; Hassan M E Azzazy
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

3.  Early IL-10 predominant responses are associated with progression to chronic hepatitis C virus infection in injecting drug users.

Authors:  J K Flynn; G J Dore; M Hellard; B Yeung; W D Rawlinson; P A White; J M Kaldor; A R Lloyd; R A Ffrench
Journal:  J Viral Hepat       Date:  2010-07-05       Impact factor: 3.728

Review 4.  Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C.

Authors:  Lesley J Scott; Caroline M Perry
Journal:  Drugs       Date:  2002       Impact factor: 9.546

5.  Relation between viral fitness and immune escape within the hepatitis C virus protease.

Authors:  J Söderholm; G Ahlén; A Kaul; L Frelin; M Alheim; C Barnfield; P Liljeström; O Weiland; D R Milich; R Bartenschlager; M Sällberg
Journal:  Gut       Date:  2005-08-16       Impact factor: 23.059

Review 6.  The hepatitis C virus persistence: how to evade the immune system?

Authors:  Nicole Pavio; Michael M C Lai
Journal:  J Biosci       Date:  2003-04       Impact factor: 1.826

7.  Hepatitis C virus mutation affects proteasomal epitope processing.

Authors:  Ulrike Seifert; Heike Liermann; Vito Racanelli; Anne Halenius; Manfred Wiese; Heiner Wedemeyer; Thomas Ruppert; Kay Rispeter; Peter Henklein; Alice Sijts; Hartmut Hengel; Peter-M Kloetzel; Barbara Rehermann
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

8.  Structural allele-specific patterns adopted by epitopes in the MHC-I cleft and reconstruction of MHC:peptide complexes to cross-reactivity assessment.

Authors:  Dinler A Antunes; Gustavo F Vieira; Maurício M Rigo; Samuel P Cibulski; Marialva Sinigaglia; José A B Chies
Journal:  PLoS One       Date:  2010-04-26       Impact factor: 3.240

9.  Immunogenicity of human mesenchymal stem cells in HLA-class I-restricted T-cell responses against viral or tumor-associated antigens.

Authors:  Fabio Morandi; Lizzia Raffaghello; Giovanna Bianchi; Francesca Meloni; Annalisa Salis; Enrico Millo; Soldano Ferrone; Vincenzo Barnaba; Vito Pistoia
Journal:  Stem Cells       Date:  2008-02-21       Impact factor: 6.277

10.  DNA vaccination protects mice against challenge with Listeria monocytogenes expressing the hepatitis C virus NS3 protein.

Authors:  Benjamin E Simon; Kenneth A Cornell; Tina R Clark; Sunwen Chou; Hugo R Rosen; Ronald A Barry
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.